TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy

Author(s): Marco Arrese, Alejandra Hernandez, Luis Astete, Lisbell Estrada, Claudio Cabello-Verrugio, Daniel Cabrera*

Journal Name: Current Protein & Peptide Science

Volume 19 , Issue 12 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.

Keywords: TGF-β, hepatocellular carcinoma, HCC, liver cancer, cirrhosis, pathogenesis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [1172 - 1179]
Pages: 8
DOI: 10.2174/1389203718666171117112619
Price: $65

Article Metrics

PDF: 65